Combined ANCA-associated vasculitis and lupus syndrome following prolonged use of hydralazine: a timely reminder of an old foe.
Sangala
N
N
Renal and Histopathology Departments, Kings Health Sciences, London 0207-188-5708, UK.
Lee
R W
RW
Horsfield
C
C
Goldsmith
D J A
DJ
D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000139:chemically induced*; D000959:Antihypertensive Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects*; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced*; D008875:Middle Aged; D013997:Time Factors
D000959:Antihypertensive Agents; D006830:Hydralazine
Int Urol Nephrol. 2007;39(1):223-31
17219015
N Engl J Med. 2004 Nov 11;351(20):2049-57
15533851
JAMA. 2007 Aug 8;298(6):655-69
17684188
Clin Exp Immunol. 1990 Sep;81(3):380-3
2168822
Br Med J (Clin Res Ed). 1984 Aug 18;289(6442):410-2
6432120
Circulation. 1953 Dec;8(6):829-39
13106903
Br Med J (Clin Res Ed). 1982 Mar 27;284(6320):936-9
6802356
Am J Kidney Dis. 1984 Jan;3(4):270-4
6229178
Br J Rheumatol. 1996 Jul;35(7):625-31
8670594
Arthritis Res Ther. 2005;7(5):R1072-81
16207324
Am J Nephrol. 1987;7(1):71-3
2883895
Arthritis Rheum. 2006 Jun 15;55(3):501-6
16739190
QJM. 1995 Nov;88(11):775-83
8542262